Cancer and Fibromyalgia: Addressing the Needs of Patients Despite Limited Research
In addition to being common yet serious diseases, both cancer and fibromyalgia bring a high burden of physical pain and negative effects on mental health.
Side Effect Management
Risk-Adapted Therapy Prevents Fungal Infections in Childhood Leukemia
Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.
New NCCN Patient Guidelines Feature Immunotherapy, CAR-T Side Effects
The NCCN recently released 2 sets of Guidelines for Patients that explain the side effects of different types of immunotherapies, such as CAR T-cell therapies.
Vitamin D May Reduce Immune Checkpoint Inhibitor–Related Colitis
Vitamin D may be used to reduce the risk of immune checkpoint inhibitor-related colitis, as well as ulcerative colitis and graft-vs-host disease.
Study Finds Vancomycin Increased Risk for Cytomegalovirus Reactivation After Hematopoietic Cell Transplant
A retrospective study of CMV-seropositive adults receiving allogeneic HCT and CMV-seronegative HLA-matched sibling donors found that vancomycin exposure before HCT increased the risk for CMV reactivation.
Study Shows That Control of Acute-Phase, Delayed-Phase Chemotherapy-Induced Vomiting in Pediatric Patients Is Poor
The level of control of acute-phase CIV in pediatric patients was lower in this study than has been reported for adult patients; control of delayed-phase CIV is also poor.
Ready-to-Dilute Liquid Formulation of Akynzeo Injection Approved
The FDA has approved a new ready-to-dilute liquid formulation of Akynzeo® injection (fosnetupitant/palonosetron; Helsinn) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, in combination with dexamethasone in adults.
Understanding Patient Needs May Increase Treatment Rates in AML
Physicians noted that patients receiving best supportive care were more likely to be interested in low-intensity treatments if the risk for side effects was lower.
Promising Early Results for Use of an Oral THC/CBD Extract As Secondary Prophylaxis in the Setting of CINV
This phase 2 study used a crossover design in which study medication and placebo were administered to all patients in cycles A and B of chemotherapy, respectively.
Are Adverse Events More Common After Radiotherapy With Immunotherapy?
Researchers aimed to determine whether the addition of radiotherapy was associated with a risk for adverse events among patients treated with ICIs.
- Loading...
Loading...
Next post in ASCO 2020
Loading... 
Loading...